Neutralizing the Threat: Pan-Ebolavirus Antibodies Close the Loop

Chad E. Mire, Thomas W. Geisbert

Research output: Contribution to journalShort surveypeer-review

11 Scopus citations


The glycoprotein (GP) of ebolaviruses participates in a critical membrane fusion process to establish infection of a cell and therefore, represents an important target of both vaccines and antivirals. The latest reports on pan-ebolavirus monoclonal antibodies in small animal models may offer promising outcomes and insight into how best to target the GP in vaccine and antiviral discovery.

Original languageEnglish (US)
Pages (from-to)669-671
Number of pages3
JournalTrends in Molecular Medicine
Issue number8
StatePublished - Aug 2017


  • Bundibugyo
  • Ebolavirus
  • Sudan
  • Zaire
  • antibody
  • treatment

ASJC Scopus subject areas

  • Molecular Medicine
  • Molecular Biology


Dive into the research topics of 'Neutralizing the Threat: Pan-Ebolavirus Antibodies Close the Loop'. Together they form a unique fingerprint.

Cite this